Coya Therapeutics Inc (COYA)

$4.86 +0.12 (2.53%)
Market Cap 97.30M
Revenue (ttm) 3.55M
Net Income (ttm) -14.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -419.15%
Debt to Equity Ratio 0.00
Volume 165,300
Avg Vol 250,010
Day's Range N/A - N/A
Shares Out 20.92M
Stochastic %K 84%
Beta 0.25
Analysts Strong Sell
Price Target $16.07

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
foreverboner
foreverboner Feb. 4 at 1:41 AM
$COYA Interview with Arun (third video scrolling down) https://www.insideprecisionmedicine.com/topics/translational-research/pills-electrodes-viruses-and-tregs-growing-medicines-toolbox/
0 · Reply
Jwa68
Jwa68 Feb. 3 at 11:02 PM
$COYA Nice accumulation occuring.
0 · Reply
Robby83
Robby83 Feb. 3 at 9:34 PM
$COYA and here I am thinking I was going to get some cheap shares this week 🙃
0 · Reply
Jwa68
Jwa68 Feb. 3 at 3:26 AM
$COYA DRL Chair says “next phase of growth must come from higher value science-led therapies"
0 · Reply
irf944
irf944 Feb. 2 at 5:33 PM
$COYA Confident as ever after Dr. Reddy invested $11M last week. Dr. Reddy is the most intimate with the science and data, and their most recent investment confirms their confidence in Coya and their progress. Everything is aligning....zero debt, plenty of cash and runway, FDA acceptance of IND, Buy ratings, and Dr. Reddy's (and Einhorn's) recent investments. Can't imagine that many shares being available with a float of 19M shares. Will not take much for SP to climb back up with low float. Some patience should be nicely rewarded.
1 · Reply
zampy
zampy Feb. 2 at 3:58 PM
$COYA 50 cents down ...$15 to $20 up.....Right people are involved..Stopping 2 indications in ALS and FTD is a major scientific breakthrough. I believe in 2026 this will be 400% to 500% higher. In it ti win it.
0 · Reply
Jwa68
Jwa68 Feb. 2 at 3:04 PM
$COYA
0 · Reply
zampy
zampy Feb. 2 at 2:03 PM
$COYA Wainwright reiterates $18 twelve month target
0 · Reply
zampy
zampy Feb. 1 at 11:48 AM
$COYA Vanguard up to 891k shares over 4.26%.
0 · Reply
zampy
zampy Jan. 31 at 2:10 PM
$COYA Vanguard increased their holdings to 891k shares.
0 · Reply
Latest News on COYA
Coya Therapeutics Announces $11.1 Million Private Placement

Jan 30, 2026, 8:00 AM EST - 4 days ago

Coya Therapeutics Announces $11.1 Million Private Placement

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Jan 20, 2026, 8:00 AM EST - 14 days ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Jan 8, 2026, 8:00 AM EST - 26 days ago

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Jan 5, 2026, 8:00 AM EST - 4 weeks ago

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Dec 23, 2025, 8:00 AM EST - 6 weeks ago

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Dec 9, 2025, 8:00 AM EST - 2 months ago

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Nov 25, 2025, 8:00 AM EST - 2 months ago

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Nov 12, 2025, 8:00 AM EST - 2 months ago

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Nov 4, 2025, 8:00 AM EST - 3 months ago

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Oct 27, 2025, 4:01 PM EDT - 3 months ago

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Oct 24, 2025, 6:30 AM EDT - 3 months ago

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Oct 23, 2025, 4:31 PM EDT - 3 months ago

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Oct 7, 2025, 8:00 AM EDT - 4 months ago

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 29, 2025, 8:00 AM EDT - 4 months ago

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 22, 2025, 8:00 AM EDT - 4 months ago

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 16, 2025, 8:00 AM EDT - 5 months ago

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

Sep 4, 2025, 8:00 AM EDT - 5 months ago

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Sep 3, 2025, 11:50 AM EDT - 5 months ago

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Sep 3, 2025, 8:34 AM EDT - 5 months ago

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Aug 25, 2025, 8:00 AM EDT - 5 months ago

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:00 AM EDT - 6 months ago

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Jul 24, 2025, 8:15 AM EDT - 6 months ago

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Jul 22, 2025, 8:15 AM EDT - 7 months ago

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Jun 18, 2025, 8:15 AM EDT - 8 months ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Jun 2, 2025, 8:00 AM EDT - 8 months ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 16, 2025, 10:53 AM EDT - 9 months ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 8:15 AM EDT - 9 months ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 9 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Apr 25, 2025, 11:27 AM EDT - 10 months ago

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 24, 2025, 8:15 AM EDT - 10 months ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 21, 2025, 9:51 AM EDT - 10 months ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Apr 1, 2025, 8:15 AM EDT - 11 months ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 26, 2025, 8:15 AM EDT - 11 months ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Mar 18, 2025, 8:15 AM EDT - 11 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 25, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Feb 7, 2025, 5:17 PM EST - 1 year ago

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Feb 7, 2025, 1:53 PM EST - 1 year ago

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Feb 6, 2025, 1:30 PM EST - 1 year ago

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Jan 21, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Dec 18, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Nov 25, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Nov 1, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Oct 31, 2024, 10:31 AM EDT - 1 year ago

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Oct 29, 2024, 2:36 PM EDT - 1 year ago

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Oct 29, 2024, 6:41 AM EDT - 1 year ago

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

foreverboner
foreverboner Feb. 4 at 1:41 AM
$COYA Interview with Arun (third video scrolling down) https://www.insideprecisionmedicine.com/topics/translational-research/pills-electrodes-viruses-and-tregs-growing-medicines-toolbox/
0 · Reply
Jwa68
Jwa68 Feb. 3 at 11:02 PM
$COYA Nice accumulation occuring.
0 · Reply
Robby83
Robby83 Feb. 3 at 9:34 PM
$COYA and here I am thinking I was going to get some cheap shares this week 🙃
0 · Reply
Jwa68
Jwa68 Feb. 3 at 3:26 AM
$COYA DRL Chair says “next phase of growth must come from higher value science-led therapies"
0 · Reply
irf944
irf944 Feb. 2 at 5:33 PM
$COYA Confident as ever after Dr. Reddy invested $11M last week. Dr. Reddy is the most intimate with the science and data, and their most recent investment confirms their confidence in Coya and their progress. Everything is aligning....zero debt, plenty of cash and runway, FDA acceptance of IND, Buy ratings, and Dr. Reddy's (and Einhorn's) recent investments. Can't imagine that many shares being available with a float of 19M shares. Will not take much for SP to climb back up with low float. Some patience should be nicely rewarded.
1 · Reply
zampy
zampy Feb. 2 at 3:58 PM
$COYA 50 cents down ...$15 to $20 up.....Right people are involved..Stopping 2 indications in ALS and FTD is a major scientific breakthrough. I believe in 2026 this will be 400% to 500% higher. In it ti win it.
0 · Reply
Jwa68
Jwa68 Feb. 2 at 3:04 PM
$COYA
0 · Reply
zampy
zampy Feb. 2 at 2:03 PM
$COYA Wainwright reiterates $18 twelve month target
0 · Reply
zampy
zampy Feb. 1 at 11:48 AM
$COYA Vanguard up to 891k shares over 4.26%.
0 · Reply
zampy
zampy Jan. 31 at 2:10 PM
$COYA Vanguard increased their holdings to 891k shares.
0 · Reply
vo2macs
vo2macs Jan. 30 at 7:18 PM
$COYA Einhorn and Dr. Reddy increased their positions. Perhaps I should to!
0 · Reply
microcapspeculator
microcapspeculator Jan. 30 at 4:49 PM
$COYA Lakestreet $17 target
1 · Reply
EmotionlessRobot
EmotionlessRobot Jan. 30 at 4:37 PM
$COYA David Einhorn is quite bearish on US stocks in general, for him to be incredibly bullish on a small cap biotech is insane. It's a very positive sign in my opinion.
1 · Reply
jwilk24
jwilk24 Jan. 30 at 3:23 PM
$COYA doubled my position here this morning
0 · Reply
jwts
jwts Jan. 30 at 3:05 PM
$COYA 2,500 to the pile at $4.62
0 · Reply
Jwa68
Jwa68 Jan. 30 at 2:57 PM
$COYA https://www.gurufocus.com/news/8566715/dr-reddys-rdy-invests-in-coya-therapeutics-private-placement
0 · Reply
foreverboner
foreverboner Jan. 30 at 2:53 PM
$COYA RDY could be getting share in the event that Coya shows compelling biomarker data and suddenly is valued beyond their purse as well.
0 · Reply
foreverboner
foreverboner Jan. 30 at 2:23 PM
$COYA Considering Greenlight just announced they will be closing to new capital on July 1st 2026, this is pretty significant.
0 · Reply
microcapspeculator
microcapspeculator Jan. 30 at 2:04 PM
$GANX $COYA Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026 - BioSpace https://www.biospace.com/deals/biotechs-next-chapter-asset-centric-deals-and-shifting-alpha-at-jpm-2026
1 · Reply
Jwa68
Jwa68 Jan. 30 at 1:47 PM
$COYA Those who know...know. They just showed their cards. If there was ever a time to consider going all in, it may be now.
2 · Reply
Jwa68
Jwa68 Jan. 30 at 1:24 PM
$COYA As anticipated, much like when Sanofi invested in $PRVB as a precursor to acquisition, give it six months here max in my mind. The parties are clearly on the path to a marriage and the strategic investment is the interim step. Speaks volumes of Dr. Reddy’s commitment and intent. They now own 9.9% of the company puttiing their money where their mouth is and helping further the drug towards commercialization. Even more encouraging and telling is billionaire David Einhorn's further commitment and adding to his position desiring to maintain his pro rata ownership at 9.9%. Cannot imagine a time where the plan was not more self evident and when those in the knows actions, so telling... The asymmetric risk never more compelling. DYDD...$XBI
2 · Reply
EmotionlessRobot
EmotionlessRobot Jan. 30 at 1:21 PM
$COYA Very good news, Reddy's and Einhorn now loving this. Might be the start of a rush to own more of the pie. "The investors in the offering are Dr. Reddy’s Laboratories, Inc. ($10 million) and Greenlight Capital ($1.1 million), an existing institutional stockholder of the Company."
1 · Reply